Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Gross Profit: 2012-2024

Historic Gross Profit for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to $149.4 million.

  • Coherus Oncology's Gross Profit rose 136.23% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.4 million, marking a year-over-year increase of 696.41%. This contributed to the annual value of $149.4 million for FY2024, which is 52.07% up from last year.
  • Per Coherus Oncology's latest filing, its Gross Profit stood at $149.4 million for FY2024, which was up 52.07% from $98.3 million recorded in FY2023.
  • In the past 5 years, Coherus Oncology's Gross Profit ranged from a high of $438.2 million in FY2020 and a low of $98.3 million during FY2023.
  • In the last 3 years, Coherus Oncology's Gross Profit had a median value of $141.0 million in 2022 and averaged $129.5 million.
  • Its Gross Profit has fluctuated over the past 5 years, first crashed by 47.59% in 2022, then skyrocketed by 52.07% in 2024.
  • Coherus Oncology's Gross Profit (Yearly) stood at $438.2 million in 2020, then crashed by 38.62% to $269.0 million in 2021, then slumped by 47.59% to $141.0 million in 2022, then plummeted by 30.30% to $98.3 million in 2023, then spiked by 52.07% to $149.4 million in 2024.